INSTITUTE FOR SYSTEMS BIOLOGY Neoadjuvant immune checkpoint blockade (ICB) is a promising treatment for melanoma and other cancer types and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult...